Neoadjuvant 5-fluorouracil, Epirubicin and Cyclophosphamide (FEC) Followed by Weekly Paclitaxel and Trastuzumab in Her2 Positive Breast Cancer
NCT01340430
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
43
Enrollment
OTHER
Sponsor class
Conditions
HER-2 Positive Breast Cancer
Interventions
DRUG:
Trastuzumab
Sponsor
Lucia Del Mastro,MD